food and drug administration, Hims and Weight loss

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Weight-loss drugs aren’t just slimming waists. They’re shifting the economy.
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.
Consumer Reports: Are weight loss drugs safe for older adults?
While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, before starting these treatments.
Weight-Loss Drugs Could Help Extend Life of Replacement Joints
Overall, the five-year risk of requiring follow-up surgery was 5.6% for those who gained weight or kept their starting weight, 4.4% for those who lost a small to moderate amount of weight, and 3.7% for those who lost a large amount, results show. Looking at specific types of replacement joints, researchers found:
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales. The online healthcare provider’s fourth-quarter revenue nearly doubled year-over-year to $481.

Queer Eye’s Jonathan Van Ness Shows Off 66-Lb. Weight Loss

Patients struggle with lack of consistent coverage for popular weight-loss drugs
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Rolling Out14h
Surprising challenges Black women face after weight loss
Discover the hidden challenges Black women face in maintaining weight loss and learn powerful strategies for long-term ...
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
Bristol Post7h
'NHS wouldn't give me weight loss jab - I paid for it and lost 9st'
A civil servant left “crying on his knees” having failed to qualify for weight loss jabs on the NHS has shed nine stone and ...
Rolling Out16h
Reasons behind sudden weight loss you shouldn’t ignore
Discover the hidden medical causes, psychological factors, and lifestyle changes that may explain the reasons for the unexpectedly weight loss.
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Surgeon says slight weight loss 'can reduce risk of common cancer by 40%'
“The average woman in the UK gains a stone in weight during her adult life, which increases the risk of breast cancer by ...
Fierce Healthcare10h
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...